Japan First in the World to Approve Dupixent ® (dupilumab) for Chronic Spontaneous Urticaria (CSU)

Approval based on results from Phase 3 trial showing Dupixent significantly reduced itch compared to placebo CSU is the fifth approved indication for Dupixent in Japan and the sixth indication for Dupixent globally TARRYTOWN, N.Y. and PARIS, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Regeneron…#dupixent #csu #ny #sanofi #welfare #regeneron #eoe #velocimmune #georgedyancopoulos #frederickwalt
Source: Reuters: Health - Category: Consumer Health News Source Type: news